Efficient induction of specific cytotoxic T lymphocytes against gastric adenocarcinoma by a survivin peptide

Biochemistry and Cell Biology

Volumn 90, Issue 6, 2012, Pages 701-708

  Gang, Yi ^a   Zhang, Xiaoyin ^a   He, Yuanlong ^a   Zheng, Jianyong ^a   Wu, Kaichun ^a   Ding, Jie ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cytotoxic T lymphocytes; Gastric adenocarcinoma; Immunotherapy; Primary cell culture; Surviving

Indexed keywords

CYTOTOXIC T LYMPHOCYTES; GASTRIC ADENOCARCINOMA; IMMUNOTHERAPY; PRIMARY CELL CULTURES; SURVIVING;

CELL CULTURE;

PEPTIDES;

EPITOPE; HLA A2 ANTIGEN; LEUCYLMETHIONYLLEUCYLGLYCYLGLUTAMYLPHENYLALANYLLEUCYLLYSYLLEUCINE; SURVIVIN; UNCLASSIFIED DRUG;

AGED; ANTINEOPLASTIC ACTIVITY; ANTITUMOR GENE; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE CULTURE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; STOMACH ADENOCARCINOMA; TUMOR CELL;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HLA-A2 ANTIGEN; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; STOMACH NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84870520546     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/o2012-028     Document Type: Article

References (27)

1. Adida C. Haioun C. Gaulard P. Lepage E. Morel P. Briere J. et al. 2000. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood, 96 (5): 1921-1925. 10961895
2. Ambrosini G. Adida C. Altieri D.C. 1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3 (8): 917-921. 10.1038/nm0897-917 9256286
3. Ambrosini G. Adida C. Sirugo G. Altieri D.C. 1998. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J. Biol. Chem. 273 (18): 11177-11182. 10.1074/jbc.273.18.11177 9556606
4. Andersen M.H. Pedersen L.O. Becker J.C. Straten P.T. 2001 a. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 61 (3): 869-872. 11221872
5. Andersen M.H. Pedersen L.O. Capeller B. Brocker E.B. Becker J.C. thor Straten P. 2001 b. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 61 (16): 5964-5968. 11507035
6. Bertazza L. Mocellin S. Marchet A. Pilati P. Gabrieli J. Scalerta R. Nitti D. 2009. Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival. J. Transl. Med. 7 (1): 111. 10.1186/1479-5876-7-111 20028510
7. Caldas H. Honsey L.E. Altura R.A. 2005. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol. Cancer, 4 (1): 11. 10.1186/1476-4598-4-11 15743529
8. Casati C. Dalerba P. Rivoltini L. Gallino G. Deho P. Rini F. et al. 2003. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res. 63 (15): 4507-4515. 12907624
9. Coughlin C.M. Fleming M.D. Carroll R.G. Pawel B.R. Hogarty M.D. Shan X. et al. 2006. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J. Clin. Oncol. 24 (36): 5725-5734. 10.1200/JCO.2005.05.3314 17179106
10. Grossman D. McNiff J.M. Li F. Altieri D.C. 1999. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Invest. Dermatol. 113 (6): 1076-1081. 10.1046/j.1523-1747.1999.00776.x 10594755
11. Li F. 2005. Role of survivin and its splice variants in tumorigenesis. Br. J. Cancer, 92 (2): 212-216. 10.1038/sj.bjc.6602340 15611788
12. Meng H. Lu C. Mabuchi H. Tanigawa N. 2004. Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett. 216 (2): 147-155. 10.1016/j.canlet.2003.12.020 15533590
13. Molldrem J.J. Lee P.P. Wang C. Champlin R.E. Davis M.M. 1999. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59 (11): 2675-2681. 10363991
14. Novellino L. Castelli C. Parmiani G. 2005. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54 (3): 187-207. 10.1007/s00262-004-0560-6 15309328
15. Patel P.R. Yao J.C. Hess K. Schnirer I. Rashid A. Ajani J.A. 2007. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer, 110 (10): 2186-2190. 10.1002/cncr.23046 17896785
16. Pita-Lopez M.L. Gayoso I. DelaRosa O. Casado J.G. Alonso C. Munoz-Gomariz E. et al. 2009. Effect of ageing on CMV-specific CD8 T cells from CMV seropositive healthy donors. Immun. Ageing, 6 (1): 11. 10.1186/1742-4933-6-11 19715573
17. Qiu K. Tomita Y. Hashimoto M. Ohsawa M. Kawano K. Wu D.M. Aozasa K. 1997. Epstein-Barr virus in gastric carcinoma in Suzhou, China and Osaka, Japan: association with clinico-pathologic factors and HLA-subtype. Int. J. Cancer, 71 (2): 155-158. 10.1002/(SICI)1097-0215(19970410)71:2<155::AID-IJC5>3.0. CO;2-# 9139835
18. Ryan B. O'Donovan N. Browne B. O'Shea C. Crown J. Hill A.D. et al. 2005. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br. J. Cancer, 92 (1): 120-124. 10.1038/sj.bjc.6602314 15611790
19. Song K.Y. Jung C.K. Park W.S. Park C.H. 2009. Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. Jpn. J. Clin. Oncol. 39 (5): 290-296. 10.1093/jjco/hyp020 19336448
20. Sørensen R.B. Svane I.M. Straten P.T. Andersen M.H. 2008. A survivin specific T-cell clone from a breast cancer patient display universal tumor cell lysis. Cancer Biol. Ther. 7 (12): 1885-1887. 10.4161/cbt.7.12.6935 18927499
21. Storkus W.J. Herrem C. Kawabe M. Cohen P.A. Bukowski R.M. Finke J.H. Wesa A.K. 2007. Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes. Crit. Rev. Immunol. 27 (5): 485-493. 10.1615/CritRevImmunol.v27.i5.60 18197809
22. Tsuruma T. Hata F. Torigoe T. Furuhata T. Idenoue S. Kurotaki T. et al. 2004. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J. Transl. Med. 2 (1): 19. 10.1186/1479-5876-2-19 15193151
23. Tsuruma T. Iwayama Y. Ohmura T. Katsuramaki T. Hata F. Furuhata T. et al. 2008. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J. Transl. Med. 6 (1): 24. 10.1186/1479-5876-6-24 18471305
24. Uenaka A. Wada H. Isobe M. Saika T. Tsuji K. Sato E. et al. 2007. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun. 7: 9. 17441676
25. Voelter V. Rufer N. Reynard S. Greub G. Brookes R. Guillaume P. et al. 2008. Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor. Int. Immunol. 20 (8): 1087-1096. 10.1093/intimm/dxn066 18573812
26. Yanagimoto H. Shiomi H. Satoi S. Mine T. Toyokawa H. Yamamoto T. et al. 2010. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol. Rep. 24 (3): 795-801. 20664989
27. Zheng W. Ma X. Wei D. Wang T. Ma Y. Yang S. 2005. Molecular cloning and bioinformatics analysis of a novel spliced variant of survivin from human breast cancer cells. DNA Seq. 16 (5): 321-328. 16329164